eccDNA Sequencing Explained: What It Measures and Why Researchers Use It (RUO)

Beginner biomedical researchers are encountering the same shift many genomics labs have felt over the past decade: the genome isn't only a set of long, tidy chromosomes. Cells also carry diverse extrachromosomal circular DNA—eccDNAs—that add unexpected layers of variation and regulation. If you've searched "eccdna nature" to understand why circles keep showing up in high-profile papers, this guide will give you a clear, practical starting point.

EccDNA (extrachromosomal circular DNA) refers to circular DNA molecules found outside chromosomal DNA in the nucleus (and occasionally in cytoplasmic fractions). They are distinct from plasmids (usually exogenous, vector-based circles in lab systems) and mitochondrial DNA (mtDNA, an endogenous circular genome confined to mitochondria). Within the umbrella of eccDNA, researchers often reserve "ecDNA" for large, highly amplified circles common in cancer that frequently carry intact oncogenes. Reviews converge on this framing: small eccDNAs are widespread across tissues, while ecDNA (often >~1 Mb) is predominantly tumor-associated and linked to amplification and heterogeneity, as outlined by Wang (2024) in an open-access review and corroborated by recent summaries of ecDNA features in cancer. See the detailed distinctions in the open-access synthesis by Wang in Unveiling the mysteries of extrachromosomal circular DNA (2024) and Zhou's discussion of ecDNA features in Frontiers in Genetics (2024).

• According to the open-access overview by Wang (2024), eccDNAs span categories from microDNA (~200 bp–3 kb) to larger elements, while ecDNA typically denotes much larger circles that often harbor entire genes.
• Zhou (2024) in Frontiers in Genetics emphasizes that ecDNA is widely present in tumors, contrasted with kilobase-sized eccDNAs found in diverse contexts.

Quick glossary (for beginners)

• eccDNA: Umbrella term for extrachromosomal circular DNA of varied sizes and origins; common across tissues and conditions.
• ecDNA: Large (>~100 kb to Mb-scale) circular DNA in cancer, frequently carrying oncogene amplifications and enhancing gene expression.
• microDNA: Small eccDNA (hundreds to a few thousand base pairs) often enriched near gene-dense or repeat regions.
• ERCs (episomal rDNA circles): Circles derived from ribosomal DNA, classically studied in yeast aging.
• Circle junction: The fusion point where a linear DNA fragment rejoins itself to form a circle; detected by split/discordant reads in sequencing.

Figure1: Simple comparison of DNA forms — linear chromosomal DNA (blue #0099d8), extrachromosomal circular DNA (eccDNA; green #82bc24), and mitochondrial DNA (orange). Size legend (not to scale): Chromosomal ≫ eccDNA (~100s bp–kb) ≈ mtDNA (~14–20 kb).

Alt text: Three-icon schematic: blue ribbon for linear chromosomal DNA, small green circles for eccDNA with a labeled junction arrow, and an orange circle inside a mitochondrion for mtDNA.

What eccDNA sequencing measures

EccDNA-oriented sequencing focuses on evidence that standard whole-genome sequencing (WGS) doesn't surface cleanly: the presence and properties of circles that exist beyond the chromosomes. Practically, you measure three core things.

1. Junction structure (how the circle is formed) Think of a circle junction as the staple point where a fragment folds back and reconnects to itself. In short-read data, you'll see split reads that map across the fusion and paired reads whose orientation suggests outward-facing junctions. In long-read data, you can sometimes traverse the entire circle. ATAC-seq—which profiles open chromatin—can also detect junctions without circle-specific enrichment by leveraging these mapping signatures. Kumar and colleagues showed in 2020 that ATAC-seq signatures predict eccDNA junctions that can be validated via inverse PCR and FISH in cancer models. See the methodological context in Kumar et al. (2020) in Science Advances and the open-access explanatory materials in the corresponding preprint/PMC resources.
2. Gene content (what genes and elements are carried) Circles can carry entire genes, gene fragments, enhancers, promoters, and repeats. Gene content matters because it hints at function: ecDNA commonly includes intact oncogenes (e.g., EGFR, MYC, MYCN) and regulatory sequences that elevate transcription. Small eccDNAs may reflect local genomic plasticity, repeat biology, or stress responses. For an accessible synthesis of roles and disease associations, see Zhao (2022) in eLife and the landscape overview by Zeng (2022) in Genome Research (open access).
3. Copy number and abundance (how much circle-derived content exists) Copy number estimates capture amplification independent of chromosomal location. In cancer, ecDNA amplicons can reach high copy numbers, segregate unevenly during cell division, and drive heterogeneity and therapy resistance. For plain-language context, the NCI Cancer Genomics program describes ecDNA as free-floating loops that supercharge oncogenes and contribute to variability across cells. See NCI CCG's ecDNA overview (2022 blog) for a readable summary.

If you want a deeper look at how samples are isolated and enriched before sequencing, jump to our step-by-step guide: Experimental workflow for eccDNA sequencing.

Core research applications

Why do researchers use eccDNA sequencing? Two application areas dominate interest and search behavior: cancer biology and aging/stress.

Cancer biology: oncogene amplification and heterogeneity

Large ecDNA circles frequently carry oncogenes such as EGFR, MYC, MYCN, and CCND2. Because they're separate from chromosomes, they can reach high copy numbers and segregate unevenly, creating cell-to-cell differences that complicate therapy. Mechanistic work shows that transcription from ecDNA can exceed chromosomal counterparts, aided by enhancer hijacking and expansive chromatin contacts. A broad 2022 review by Yi and colleagues summarizes recurrent oncogene loci on ecDNA in multiple tumor types, while accessible overviews from NCI highlight heterogeneity and resistance.

Real-world vignettes help cement the concepts:

• Glioblastoma (GBM): EGFR amplification is a classic ecDNA example in GBM, where unequal segregation produces mosaic expression and response patterns; ATAC-seq can reveal early junction signatures before full amplification is apparent. Kumar's study provides the foundational mapping logic: Science Advances (2020).
• Small cell lung cancer (SCLC): MYC/MYCN ecDNA units demonstrate how enhancer-rich amplicons elevate transcription beyond chromosomal comparators, contributing to aggressive phenotypes, as summarized across reviews like Yi (2022).

Discover how these circles drive tumor heterogeneity in our series article: eccDNA in cancer.

Aging and stress: accumulation and cellular senescence contexts

EccDNA has a long history in yeast aging: ERCs accumulate in mother cells, contributing to senescence via replication and transcriptional effects. Mammalian evidence is nuanced—eccDNAs are present in normal and cancerous tissues, and some contexts show differential profiles with aging or stress. Wang's 2024 review consolidates subtypes and potential functions, while Zeng's 2022 landscape highlights distributions across tissues. In plasma, eccDNA shows distinctive size periodicity compared with linear cfDNA, consistent with nucleosomal packaging effects, as reported by Sin and colleagues.

• Yeast ERCs: Classic models show ERC accumulation and age-associated phenotypes in mother cells; see modern summaries in DNA circles promote yeast ageing (eLife, 2022) and Transcription‑induced formation of eccDNA in yeast (PLoS Biology, 2019).
• Plasma/cfDNA: Distinct eccDNA size peaks (~202 bp, ~338 bp) compared with the 166 bp modal linear cfDNA, reflecting chromatin context; see Sin (2020) in PNAS.

Explore the role of circular DNA in cellular senescence and somatic biology in our series article: eccDNA in somatic cells and aging.

Methods overview: how do we sequence circles?

There isn't a single "eccDNA kit" that fits every question. Most labs choose among three high-level routes, often combining them for validation.

• Exonuclease digestion + Rolling Circle Amplification (RCA): ATP-dependent exonucleases (e.g., Plasmid-Safe) remove linear DNA; phi29 polymerase amplifies circular templates. This backbone underpins many Circle-Seq workflows. It's efficient for small circles but can bias against larger ones and may create concatemer artifacts if conditions aren't tuned. Practical insights and protocol scaffolds appear in Møller (2020) describing Circle-Seq and synthesis pieces such as Yu (2023) on Circle-Seq variants.
• Tn5/tagmentation-based approaches: Circulome-seq and ATAC-seq leverage Tn5 transposition to tag accessible DNA, capturing junction signatures without RCA. They reduce some amplification biases but can demand higher sequencing depth and careful bioinformatic filtering. See Kumar (2020) in Science Advances and the open-access materials linked therein.
• Non-RCA enrichment for native small circles: Some workflows enrich small circles via exonuclease cleanup without RCA, preserving native size distributions and reducing chimeras. Comparative performance discussions appear in recent methods syntheses like Gao (2024) on long-read reconstruction and enrichment trade-offs.

Key planning considerations (beginner-friendly)

• Sample prep: Nuclei isolation quality influences linear DNA depletion efficiency; gentle handling reduces shearing that can confound junction calls.
• Controls: Include spike-in plasmids to track circular:linear ratios; quantify mtDNA carryover; add mock-digestion controls to detect incomplete exonuclease cleanup.
• Library construction: For RCA-derived material, limit amplification cycles to reduce concatemers; for ATAC-seq, optimize transposition to balance sensitivity and specificity.
• Sequencing strategy: Short-read Illumina is common for Circle-Seq; add long-read ONT/PacBio when you expect large circles or complex rearrangements.

For strategy differences and controls to include, compare options in our series article: Choosing eccDNA enrichment methods.

• For labs that prefer an outsourced RUO option, service providers can run exonuclease digestion plus RCA and return junction and gene-content reports; see CD Genomics' Oncology research solutions for study planning and RUO sequencing support.

Disclosure: CD Genomics is our product. Neutral example of service execution: providers such as CD Genomics can perform RUO eccDNA workflows (e.g., exonuclease digestion plus RCA) and deliver junction- and gene-content reports with appropriate QC, when projects require external support. Mentioned here for context only.

Figure 1: Concept schematic. Chromosomal DNA is long and linear; eccDNAs are diverse small circles often derived from chromosomal fragments; mtDNA is a separate circular genome in mitochondria.

Figure 2: Stylized EM/AFM-inspired drawing. Small eccDNAs appear as thin loops; a larger loop represents cancer-associated ecDNA. This is an illustrative sketch, not a micrograph.

Practical planning for beginners (RUO)

To make the concepts concrete, here are two mini-projects and a troubleshooting checklist that beginners can adapt for research use only.

Mini-project 1: Pilot profiling in a cancer cell line

• Goal: Detect ecDNA carrying an oncogene (e.g., EGFR) in a glioblastoma line.
• Route: Prepare nuclei, perform exonuclease digestion to remove linear DNA, then RCA to amplify circles; construct an Illumina library.
• Expected output: Circle calls with junction coordinates; elevated coverage over EGFR; split-read support across junctions.
• Validation: Outward-facing PCR across the junction and Sanger sequencing; optional FISH for localization.
• Notes: RCA conditions can bias toward small circles; consider complementary Tn5-based detection of junctions and, if resources allow, long-read validation for larger structures.

Figure 3. Pilot workflow for ecDNA profiling in a cancer cell line.

Mini-project 2: Detecting a circle junction from split reads (ATAC-seq)

• Goal: Identify pre-amplification junctions in the same line using ATAC-seq signatures.
• Route: Perform ATAC-seq; analyze for split reads and outward-facing pairs that map non-linearly; flag candidates near EGFR.
• Expected output: Junction candidates corroborated by inverse PCR; potential hotspots where ecDNA later emerges.
• Notes: ATAC-seq captures accessible chromatin; depth and bioinformatic filters matter. See methodological context in Kumar (2020).

Troubleshooting box: common pitfalls and controls

• mtDNA carryover: Because mtDNA is circular, incomplete cleanup can inflate "circle" signals. Include mtDNA-specific quantification as a background check.
• Incomplete exonuclease digestion: Residual linear DNA can mimic junction signatures. Use spike-in plasmid controls to quantify circular:linear ratios and optimize digestion.
• RCA concatemer artifacts: Over-amplification can create artificial chimeras. Titrate phi29, limit reaction time, and include post-RCA cleanup. Consider non-RCA enrichment for small circles when artifacts dominate.
• Restriction/tagmentation bias: Enzymes like MspI impose motif preferences. If your study involves differential motif content, consider complementary methods.
• Insufficient sequencing depth/length: Shallow depth misses junctions; add long reads or inverse PCR for key targets.

Bioinformatics primer: from reads to circles

Beginners often ask, "How will the results look?" Here's a concise map of expected outputs and common tools.

Detection logic (short-read)

• Split reads: single reads that align to two adjacent genomic segments that are not contiguous in the reference, crossing the circle junction.
• Discordant pairs: mate-pair orientations and distances that suggest a looped fusion.
• Junction support: tools count supporting reads and estimate confidence; outward PCR provides orthogonal validation.

Tools you'll encounter

• Circle-Map and related short-read tools report candidate circles with coordinates, lengths, and read-support metrics. See an integrated discussion in Fang (2024) on eccDNA-pipe and tool comparisons.
• AmpliconArchitect (AA) reconstructs amplified structures, commonly used for ecDNA amplicons in cancer.
• Long-read workflows (e.g., CReSIL) help traverse large circles and map internal rearrangements. See comparative notes in Gao (2024).

Expected report fields (minimal template)

• Circle ID and genomic coordinates (e.g., hg38 chr7:54,000,000–54,250,000).
• Junction read support (split reads, discordant pairs) and confidence score.
• Length and sequence composition (repeats, enhancers, gene overlap).
• Sample metadata (cell line, treatment) and condition.
• Copy number estimate or coverage-based abundance metrics.

Reporting and quality standards (beginner checklist)

• Enrichment efficiency: Document circular:linear ratios using spike-in plasmids or endogenous references (mtDNA), aiming for high post-enrichment ratios to ensure specificity.
• Background/chimeric rates: Track potential RCA concatenation artifacts and junction calls with low support; consider orthogonal validation.
• Reproducibility: Report replicate concordance and per-sample eccDNA counts normalized to sequencing depth.
• Validation: Include outward PCR/Sanger confirmation for representative junctions; optional FISH for large ecDNA localization.

Figure 4: Brand-color Circos-style example. Green track indicates hypothetical eccDNA counts; blue marks gene overlaps. Hotspots near known oncogenes and repeat-rich regions are labeled for orientation.

Optional next read in the series: a deeper dive into pipelines, filtering artifacts, and reporting standards in Bioinformatics for eccDNA: detection, filtering, and reporting.

If you plan to outsource analysis, ask for a results package that includes junction coordinates, read‑support metrics, and gene annotations — many teams engage CD Genomics for NGS bioinformatics analysis to produce publication-ready reports.

Study design considerations: sample types, depth, and controls (RUO)

Planning a study that will generate interpretable eccDNA data comes down to three practical decisions: what samples you'll run, how deeply you'll sequence, and which controls you'll include.

Sample types and collection

• Cultured cells: Provide clean nuclei for exonuclease-based workflows; easy to scale and replicate.
• Tumor tissues: Heterogeneity complicates interpretation; consider microdissection or single-cell adaptations if feasible.
• Plasma/cfDNA: Non-invasive sampling; expect distinct circle size peaks and higher background; enzymatic cleanup is critical.

Depth and platform choices

• Short-read (Illumina): Common for Circle-Seq; target sufficient depth to detect low-abundance circles and support robust junction calls.
• Long-read (ONT/PacBio): Adds confidence for large circles and complex structures; plan for >10X coverage on targets of interest when possible.
• ATAC-seq adjunct: Useful to flag junctions and accessible regions that may precede ecDNA amplification.

Controls and QC

• Spike-ins: Plasmid spike-ins to estimate circular enrichment efficiency and monitor losses.
• Negative controls: Mock-digestion samples to reveal incomplete linear DNA removal; no-template controls to detect amplification artifacts.
• Orthogonal validation: Outward PCR and Sanger; optional FISH or pulsed-field gel electrophoresis (PFGE) for purity checks.

For QC metrics across eccDNA projects—enrichment efficiency, background, reproducibility—see the series guide on Quality metrics for eccDNA sequencing.

FAQ for first-time eccDNA readers

• Do eccDNAs and ecDNA mean the same thing? No. "eccDNA" is the umbrella term covering diverse circular DNA molecules. "ecDNA" usually refers to large, amplification-bearing circles common in cancer that frequently carry entire oncogenes. For size/function distinctions, see Wang (2024) and Zhou (2024).
• Are small eccDNAs just artifacts of library prep? Not in general. Multiple assays—including non-RCA enrichments and ATAC-seq junction detection—support the existence of small eccDNAs across contexts. Method choice and controls matter to avoid RCA concatemers or incomplete linear DNA cleanup. See methodological discussions in Yu (2023) and Kumar (2020).
• What samples can be profiled? Many: cultured cells, tissues, and even plasma/cfDNA. Plasma studies using exonuclease V (ExoV) plus restriction enzymes (e.g., MspI) have reported distinct size peaks for eccDNA compared with linear cfDNA, reflecting nucleosomal periodicity. See Sin (2020) in PNAS.
• How do I validate circle calls? Use outward-facing PCR across junctions and Sanger sequencing; FISH can localize large ecDNA; long-read sequencing or inverse PCR can provide additional confirmation.
• Is there a database of known circles? Aggregators like CircleBase V2 and eccDNABase compile coordinates, annotations, and sample metadata across species. See CircleBase V2 (2025) and eccDNABase (2024).

Conclusion and next steps (RUO)

EccDNA sequencing expands the way we view genome structure and variability. By measuring junctions, gene content, and amplification beyond the chromosomes, researchers can track how circles shape cancer heterogeneity and explore their roles in somatic biology and aging. The field's momentum—visible in "eccdna nature" publications—comes from connecting clear evidence (junctions, gene content, copy number) to meaningful biological questions.

If you're planning a RUO project and need external support, providers such as CD Genomics offer relevant services. Explore Oncology Research solutions on CD Genomics and comprehensive Bioinformatics services to discuss study design and reporting needs.

For deeper learning in this series:

• Methods and controls: Choosing eccDNA enrichment methods
• End-to-end lab guide: Experimental workflow for eccDNA sequencing
• Cancer applications: eccDNA in cancer
• Aging and somatic biology: eccDNA in somatic cells and aging
• Bioinformatics and reporting: Bioinformatics for eccDNA: detection, filtering, and reporting
• QC and reproducibility: Quality metrics for eccDNA sequencing

For RUO project support—study design, sequencing, and downstream reporting—contact CD Genomics' Oncology research solutions and Genomic data analysis solutions to discuss experimental scope and deliverables.

References:

1. Wang, X. et al., "Unveiling the mysteries of extrachromosomal circular DNA" (review, 2024) — authoritative open-access review summarizing eccDNA classes, sizes, and functions; see Wang 2024 review (PMC).
2. Zhou, Y., "ecDNA features and tumor distribution" (Frontiers in Genetics, 2024) — discussion of ecDNA definitions and tumor prevalence; see Zhou 2024, Frontiers in Genetics.
3. Zeng, W. et al., "Landscape of eccDNA in normal hematopoiesis and leukemia evolution" (Genome Research, 2022) — open-access landscape paper on eccDNA distribution across tissues; see Zeng 2022, Genome Research (PMC).
4. Zhao, X. et al., "Extrachromosomal circular DNA roles and tumor association" (eLife, 2022) — review of eccDNA biology and disease links; see Zhao 2022, eLife.
5. Kumar, P. et al., "ATAC-seq identifies extrachromosomal circular DNA junctions" (Science Advances, 2020) — demonstrates ATAC-seq signatures for eccDNA junction detection and validation; see Kumar 2020, Science Advances and the open-access record Kumar et al. (PMC).
6. Yu, L. et al., "Circle-Seq variants and practical insights" (methods review, 2023) — practical Circle-Seq synthesis and validation notes; see Yu 2023 (PMC).
7. Møller, H.D., "Circle-Seq protocol" (Nature Protocols / PubMed, 2020) — original Circle-Seq protocol and stepwise guidance; see Møller 2020 protocol (PubMed).
8. Fang, Z. et al., "eccDNA-pipe and tool comparisons" (Briefings in Bioinformatics, 2024) — integrated workflow and tool benchmarking for eccDNA detection; see Fang 2024, Briefings in Bioinformatics.
9. Gao, Y. et al., "Long-read reconstruction and enrichment trade-offs (CReSIL)" (methods comparison, 2024) — long-read reconstruction and enrichment performance discussion; see Gao 2024 (PMC).
10. Sin, H.S. et al., "Plasma eccDNA enrichment using ExoV and restriction enzymes" (PNAS, 2020) — methods and size-profile observations for plasma eccDNA; see Sin 2020, PNAS.
11. National Cancer Institute, Cancer Genomics Program — "ecDNA overview and implications" (NCI CCG blog, 2022) — accessible summary of ecDNA biology in cancer; see NCI CCG ecDNA overview (2022).
12. CircleBase V2 — curated eccDNA database (2025 landing/PMC article) — aggregated coordinates and annotations across studies; see CircleBase V2 (PMC).
13. eccDNABase — comprehensive eccDNA database description and resource (MBE/OUP) — see eccDNABase (2024/2025, MBE).

Author

Yang H. — Senior Scientist, CD Genomics; University of Florida.

Yang is a genomics researcher with over 10 years of research experience in genetics, molecular and cellular biology, sequencing workflows, and bioinformatic analysis. Skilled in both laboratory techniques and data interpretation, Yang supports RUO study design and NGS-based projects.